Antares Pharma (ATRS) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Antares Pharma Reports First Quarter 2018 Operating and Financial Results
May 8, 2018 7:00 AM EDTEWING, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today reported operating and financial results for the first quarter ended March 31, 2018. The Company reported revenue of $12.7 million and a net loss per share of $0.04 for the quarter ended March 31, 2018.
Our first quarter results were highlighted by an increase in product sales, total revenue and the FDA approval and launch of our partners Makena subcutaneous auto injector product, which was developed utilizing our QuickShot auto injector technology. This approval further validates our expertise in developing proprietary... More
